HIV-1 Vaccine Test in Uninfected Adult Volunteers

* INCLUSION CRITERIA: A participant must meet all of the following criteria: * 18 to 40 years old. * Available for follow-up for the duration of the study (12 months). * Able to provide proof of identity to the acceptance of the study clinician completing the enrollment process. * Complete an Assessment of Understanding prior to enrollment and verbalize understanding of all questions answered incorrectly. * Able and willing to sign the informed consent form. * Willing to receive HIV test results and willing to abide by NIH guidelines for partner notification of positive HIV results. * Willing to have blood samples used for future research. * Willing to discuss HIV infection risks and amenable to risk reduction counseling. * In good general health without clinically significant medical history. * Physical examination and laboratory results without clinically significant findings within the 28 days prior to enrollment. Laboratory Criteria within 28 days prior to enrollment: * Hematocrit greater than or equal to 34 percent for women; greater than or equal to 38 percent for men. * WBC count: Non-African Americans equals 3,300-12,000 cells/mm(3); African-Americans equals 2,500-12,000 cells/mm(3) (in the absence of clinical or pathological etiology). * Differential either within institutional normal range or accompanied by site physician approval. * Total lymphocyte count: Non-African Americans greater than or equal to 800 cells/mm(3); African Americans greater than or equal to 650 cells/mm(3) (in the absence of clinical or pathological etiology). * Platelets equals 125,000-550,000/mm(3). * ALT (SGPT) less than or equal to 1.5 times upper limit of normal. * Serum creatinine less than or equal to 1.3 mg/dL. * Normal urinalysis defined as negative glucose, negative or trace protein, and negative or trace hemoglobin (blood). * Negative FDA-approved HIV blood test. * Negative Hepatitis B surface antigen. * Negative anti-HCV or negative HCV PCR if the anti-HCV is positive. Female-Specific Criteria: * Negative beta-HCG pregnancy test for women presumed to be of reproductive potential. * A female participant must meet one of the following criteria: No reproductive potential because of menopause \[one year without menses\] or because of a hysterectomy, bilateral oophorectomy, or tubal ligation, Or -Participant agrees to be heterosexually inactive at least 21 days prior to enrollment and throughout the duration of the study, Or * Participant agrees to consistently practice contraception at least 21 days prior to enrollment and throughout the duration of the study by one of the following methods: * condoms, male or female, with or without a spermicide. * diaphragm or cervical cap with spermicide. * intrauterine device. * contraceptive pills, Norplant, or Depo-Provera. * male partner has previously undergone a vasectomy for which there is documentation. EXCLUSION CRITERIA: A volunteer will be excluded if one or more of the following conditions apply: -Woman who is breast-feeding. Volunteer has received any of the following substances: * HIV vaccines in a prior clinical trial. * Immunosuppressive or cytotoxic medications within the past six months with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis. * Blood products within 120 days prior to HIV screening. * Immunoglobulin within 60 days prior to HIV screening. * Live attenuated vaccines within 30 days prior to initial study vaccine administration. * Investigational research agents within 30 days prior to initial study vaccine administration. * Medically indicated subunit or killed vaccines ( e.g., influenza, pneumococcal, or allergy treatment with antigen injections) within 14 days of study vaccine administration. * Current anti-TB prophylaxis or therapy. Volunteer has a history of any of the following clinically significant conditions: * Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty angioedema, or abdominal pain. * Autoimmune disease or immunodeficiency. * Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids. * Diabetes mellitus (type I or II), with the exception of gestational diabetes. * Thyroid disease including history of thyroidectomy and diagnoses that required medication within the past 12 months. * Serious angioedema episodes within the previous 3 years or requiring medication in the previous 2 years. * Hypertension that is not well controlled by medication or is more than 150/100 at enrollment. * Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws. * Syphilis infection that is active or a positive serology due to a syphilis infection treated less than six months ago. * Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of the study. * Seizure disorder other than: 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring prolonged treatment more than 3 years ago. * Asplenia or any condition resulting in the absence or removal of the spleen. * Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment. * Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgement of the investigator, would interfere with or serve as a contraindication to protocol adherence or a volunteer's ability to give informed consent.